Bluebird's Lyfgenia launch gains traction but shares tumble with report of accounting errors
Fierce Pharma
MARCH 26, 2024
Bluebird bio reported progress of its launch of three gene therapies and said it will have to refile financial statements because of accounting errors
Let's personalize your content